Evolving Acceptance of Quality of Life in Drug Development

The chapter delves into the changing attitudes towards patient-reported outcomes and quality of life in drug development, particularly among European regulators. It explores the challenges and initiatives, like the SISACORE project, aimed at setting global standards in this area. The conversation also emphasizes the increasing need for collaboration between regulatory agencies and payers for a more patient-centric approach.